Comprehensive Guide to Alzheimer’s Treatment Medications: Options, Dosages, and Safety Tips

Alzheimer’s disease medications are prescribed to relieve symptoms and improve daily functioning. They belong to several pharmacologic classes, each acting on a different neurochemical pathway.

Below is a concise overview of the major drug categories.

Cholinesterase inhibitors

These agents boost acetylcholine, a neurotransmitter that is typically depleted in Alzheimer’s patients, thereby supporting memory and reasoning.

Commonly used drugs include:

• Donepezil (Aricept): Approved for mild‑to‑moderate disease and, in higher doses, for severe cases. It raises acetylcholine levels to improve neuronal communication.
• Rivastigmine (Exelon): Available as oral tablets or a transdermal patch. Indicated for mild‑to‑moderate Alzheimer’s and Parkinson’s‑related dementia.
• Galantamine (Razadyne): Used for mild‑to‑moderate disease; it both inhibits cholinesterase and promotes acetylcholine release.

NMDA‑receptor antagonists

These drugs modulate glutamate activity, preventing excitotoxic damage that can accelerate cognitive decline.

The most frequently prescribed agent is Memantine (Namenda), indicated for moderate‑to‑severe Alzheimer’s. It stabilizes glutamate signaling, helping preserve memory and learning.

Combination therapy

Combining a cholinesterase inhibitor with an NMDA‑receptor antagonist addresses multiple disease mechanisms at once.

Namzaric (donepezil + memantine) is the FDA‑approved single‑pill regimen for moderate‑to‑severe Alzheimer’s, designed to enhance overall cognition and symptom control.

Donepezil (Aricept)

Donepezil increases acetylcholine, supporting memory and attention. It does not halt disease progression.

Typical dosing: start 5 mg daily, titrate to 10 mg; severe cases may require 23 mg.

Common adverse effects: nausea, diarrhea, insomnia, muscle cramps, fatigue. Serious risks include bradycardia and gastrointestinal bleeding. Interactions may occur with anticholinergics, NSAIDs, and other agents that affect heart rate or gut motility.

Rivastigmine (Exelon)

Rivastigmine also raises acetylcholine levels and is available in two formulations.

• Oral tablets: start 1.5 mg twice daily, max 6 mg twice daily (12 mg total).
• Transdermal patch: start 4.6 mg/day, may increase to 9.5 mg/day, with an optional 13.3 mg/day ceiling.

Typical side effects: nausea, vomiting, diarrhea, loss of appetite, weight loss. Severe events can involve gastrointestinal complications and cardiac issues. Caution with other cholinesterase inhibitors and drugs that raise bleeding risk.

Galantamine (Razadyne)

In addition to cholinesterase inhibition, galantamine potentiates nicotinic receptors, further enhancing acetylcholine activity.

A 2015 clinical trial reported that a daily dose of 24 mg significantly improved cognitive scores.

Usual dosing: start 4 mg twice daily, max 12 mg twice daily; extended‑release tablets begin at 8 mg once daily, max 24 mg daily.

Common adverse events: nausea, vomiting, diarrhea, dizziness, headache. Serious concerns include liver toxicity and bradycardia. Interactions may occur with other cholinesterase inhibitors and CYP‑mediated drugs such as certain antibiotics and antifungals.

Memantine (Namenda)

Memantine regulates glutamate to protect neurons from overstimulation.

Evidence suggests that about 1 in 10 patients experience a slowing of functional decline over six months, with added benefits for agitation and mood.

Typical titration: start 5 mg once daily, increase to a target of 20 mg per day (10 mg twice daily).

Side effects: dizziness, headache, confusion, constipation, elevated blood pressure. Rare but severe allergic reactions have been reported. Monitor renal function and avoid concomitant drugs that alter urinary pH.

Namzaric (donepezil + memantine)

Combining both mechanisms in a single tablet simplifies regimens for moderate‑to‑severe disease.

A 2020 study demonstrated superior outcomes versus placebo for cognition, overall health, daily activities, and mood, though tolerability was lower than when each drug was taken separately.

Dosage is individualized, generally delivering donepezil 10–23 mg and memantine 10–20 mg per day.

Adverse effects reflect those of the component drugs (nausea, diarrhea, dizziness, fatigue). Interactions may involve agents that affect cardiac rhythm, gastrointestinal motility, or renal clearance.

Aducanumab (Aduhelm)

Aducanumab is a monoclonal antibody that targets amyloid‑beta plaques. It is administered intravenously every four weeks after an initial loading phase.

Results from two pivotal trials were mixed: a high‑dose regimen produced a 22 % reduction in clinical decline in one study, while the other showed no statistically significant benefit. Both confirmed amyloid‑beta reduction.

Key safety concerns include amyloid‑related imaging abnormalities—brain swelling (ARIA‑E) and microhemorrhages (ARIA‑H)—as well as headache and confusion. Careful monitoring is required, especially when combined with anticoagulants or other CNS‑active agents.

Emerging disease‑modifying therapies

Research is expanding beyond symptom control toward agents that address underlying pathology:

• Lecanemab (Leqembi): FDA‑accelerated approval in 2023; anti‑amyloid antibody with promising cognitive outcomes.
• Donanemab (Kisunla): Early trials suggest slowing of decline in early Alzheimer’s.
• Gene‑editing approaches: CRISPR‑based strategies aim to correct pathogenic mutations (pre‑clinical stage).
• BACE inhibitors: Target beta‑secretase to reduce amyloid production; ongoing optimization after mixed trial results.
• Neuroinflammation modulators: Agents such as AL002 target microglial activation.
• Stem‑cell and neuroprotective strategies: Investigating cellular regeneration, mitochondrial support, and sirtuin activation.
• Lifestyle and supplement programs: Diet, exercise, cognitive training, omega‑3 fatty acids, and antioxidants are being studied for synergistic benefits.

Practical medication‑management tips

• Establish a routine: Take each dose at the same time each day, preferably with a meal.
• Set reminders: Use phone alarms or dedicated medication‑tracking apps.
• Use a pill organizer: Weekly or monthly compartments help prevent missed or double doses.
• Maintain a log: Record date, time, and any observed effects.
• Know your regimen: Understand the purpose and common side effects of each medication.
• Prevent interactions: Inform your healthcare team of all prescription drugs, over‑the‑counter products, and supplements.
• Discuss simplification: Ask your clinician about combination pills or alternate dosing schedules.
• Monitor for adverse effects: Report new symptoms promptly; a caregiver can assist with observation.
• Plan for missed doses: Follow your prescriber’s guidance—usually, skip the missed dose and resume the regular schedule.
• Stay hydrated: Adequate fluid intake supports overall health unless contraindicated.

While no medication can cure Alzheimer’s, these treatments are essential for symptom management and maintaining quality of life. Ongoing communication with your neurologist or geriatrician ensures the regimen remains optimal as the disease evolves.